HLF - Sensei downgraded PT cut on program discontinuation Gilead's Yescarta data and more in analyst action

Alex Potemkin/iStock Unreleased via Getty Images Sensei downgraded, price trimmed on program discontinuation Oppenheimer has downgraded shares of Sensei Biotherapeutics (SNSE) from outperform to perform and has removed its $36 price target in the wake of discontinuing the SNS-301 program for squamous cell head and neck cancer. Analyst Kevin DeGeeter says that while he is disappointed with the new data, he does not believe it will impact the company's other programs as human aspartate ?-hydroxylase ("ASPH"), a tumor-associated antigen "is a novel antigen with limited tumor specificity." By now prioritizing the next-generation ImmunoPhage, SNS-401-NG, and the checkpoint antibody SNS-VISTA, DeGeeter says this "mix of novel and well characterized antigens...should provide a cleaner assessment of the phage platform." Citi is maintaining its buy rating on shares, but is cutting its price target by more than half from $30 to $14. The firm adds the company will now face short-term challenges. However, analyst Mohit Bansal

For further details see:

Sensei downgraded, PT cut on program discontinuation, Gilead's Yescarta data, and more in analyst action